coumarin has been researched along with Parkinson Disease in 4 studies
2H-chromen-2-one: coumarin derivative
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, H | 1 |
| Maeng, HJ | 1 |
| Kim, JH | 1 |
| Yoon, JH | 1 |
| Oh, Y | 1 |
| Paek, SM | 1 |
| Lee, Y | 1 |
| Rodríguez-Enríquez, F | 1 |
| Costas-Lago, MC | 1 |
| Besada, P | 1 |
| Alonso-Pena, M | 1 |
| Torres-Terán, I | 1 |
| Viña, D | 1 |
| Fontenla, JÁ | 1 |
| Sturlese, M | 1 |
| Moro, S | 1 |
| Quezada, E | 1 |
| Terán, C | 1 |
| Fernandes, C | 1 |
| Martins, C | 1 |
| Fonseca, A | 1 |
| Nunes, R | 1 |
| Matos, MJ | 1 |
| Silva, R | 1 |
| Garrido, J | 1 |
| Sarmento, B | 1 |
| Remião, F | 1 |
| Otero-Espinar, FJ | 1 |
| Uriarte, E | 1 |
| Borges, F | 1 |
| Yap, AC | 1 |
| Mahamad, UA | 1 |
| Lim, SY | 1 |
| Kim, HJ | 1 |
| Choo, YM | 1 |
4 other studies available for coumarin and Parkinson Disease
| Article | Year |
|---|---|
Synthetic Peucedanocoumarin IV Prevents α-Synuclein Neurotoxicity in an Animal Model of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Coumarins; Disease Models, Animal; Dopaminergic Neurons; Mice; Parkinson D | 2022 |
Novel coumarin-pyridazine hybrids as selective MAO-B inhibitors for the Parkinson's disease therapy.
Topics: Animals; Coumarins; Dose-Response Relationship, Drug; Humans; Injections, Intraperitoneal; Male; Mic | 2020 |
PEGylated PLGA Nanoparticles As a Smart Carrier to Increase the Cellular Uptake of a Coumarin-Based Monoamine Oxidase B Inhibitor.
Topics: Caco-2 Cells; Cell Line, Tumor; Coumarins; Drug Carriers; Humans; Inhibitory Concentration 50; Micro | 2018 |
A coumarin-based fluorescent probe as a central nervous system disease biomarker.
Topics: Biomarkers; Biosensing Techniques; Coumarins; Fluorescent Dyes; Homocysteine; Humans; Methylmalonic | 2014 |